



**Shipment to:**

Kinderspital Zürich  
ZPL – Fachbereich Hämatologie  
Steinwiesstrasse 75  
CH-8032 Zürich

**Contact:**

Cytomorphology: 044 266 75 99  
Immunphenotyping/FCM-MRD: 044 266 31 10  
Moleculargenetics/PCR-MRD: 044 266 75 74  
Cytogenomics: 044 266 78 49

**Laboratory Shipment Form for Leukemia**

**Patient**

Name: \_\_\_\_\_  
First name: \_\_\_\_\_  
Date of birth: \_\_\_\_\_

**Sender**

Address: \_\_\_\_\_  
  
Treating physician: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Collection date: \_\_\_\_\_

**Diagnosis (suspected diagnosis)**

Therapy protocol:

- AIEOP-BFM ALL 2017
- IntReALL SR 2010 / ALL Relapse
- IntReALL HR 2010
- EsPhALL2017/COGAALL1631
- MyeChild 01
- ML-DS 2018
- other: \_\_\_\_\_

Date of initial diagnosis: \_\_\_\_\_

- Under treatment:  yes /  no
- Pretreatment:  Transfusions  Neupogen
- Therapy timepoint: \_\_\_\_\_

**Diagnostics / Follow-up diagnostics (see following pages, please enclose required pages)**

Laboratory values: Please enclose copy of lab report

Leukocytes _____ G/L	Liquor cell count: _____ /µL
Erythrocytes _____ T/L	Nucleated cells _____ /µL
Hemoglobin _____ g/L	Erythrocytes LQ _____ /µL
Thrombocytes _____ G/L	Macroscop. contaminated with blood? <input type="checkbox"/> yes / <input type="checkbox"/> no

**Material**

- Blood smears (6 unstained)
- Bone marrow smears (6-8 unstained)  
Puncture site: \_\_\_\_\_
- Heparin-bone marrow  
(ideally 3x 5ml in tubes without beads and gel, if possible please perform puncture at 2 sites in the bone through the same puncture site in the skin)
- Liquor (2 cytopspins unstained)
- Heparin-blood
- EDTA-blood
- other: \_\_\_\_\_

## Accompanying note AIEOP-BFM ALL 2017

AIEOP-BFM ALL 2017	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
<b>All patients</b>				
<input type="checkbox"/> initial	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> day 8	PB smears			
<input type="checkbox"/> day 15	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 33 (TP 1)	BM smears		Heparin-BM	
<input type="checkbox"/> day 78/92 (TP 2)	BM smears*		Heparin-BM	
<b>non-HR</b>				
<input type="checkbox"/> before protocol II	BM smears*		Heparin-BM	
<b>HR</b>				
<input type="checkbox"/> after HR-1 (TP HR1)	BM smears*		Heparin-BM	
<input type="checkbox"/> after HR-2 (TP HR2)	BM smears*		Heparin-BM	
<input type="checkbox"/> after HR-3 (TP HR3)	BM smears*		Heparin-BM	
<input type="checkbox"/> after DNX-FLA (TP D/F)	BM smears*		Heparin-BM	
<input type="checkbox"/> before protocol III <input type="checkbox"/> 1. <input type="checkbox"/> 2. <input type="checkbox"/> 3.	BM smears*		Heparin-BM	
<input type="checkbox"/> before HSCT	BM smears*		Heparin-BM	
<input type="checkbox"/> other timepoint:				
<b>Randomized treatment arms:</b>				
<b>R-eHR (pB-ALL)</b>				
<input type="checkbox"/> day 64 Consol Bext (TP1a)	BM smears*		Heparin-BM	
<b>R-HR (pB-ALL)</b>				
<b>Control arm</b>				
<input type="checkbox"/> after HR-2 (TP HR2)	BM smears*		Heparin-BM	
<input type="checkbox"/> after HR-3 (TP HR3)	BM smears*		Heparin-BM	
<b>Experimental arm</b>				
<input type="checkbox"/> start Blina Cycle 1 (TP HR Blina d1)	BM smears*	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 15 Blina Cycle (TP HR Blina d15)	BM smears*		Heparin-BM	
<input type="checkbox"/> day 29 Blina Cycle 1 (TP HR Blina1 d29)	BM smears*	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 29 Blina Cycle 2 (TP HR Blina2 d29)	BM smears*	Heparin-BM	Heparin-BM	
<b>R-MR (pB-ALL)</b>				
<input type="checkbox"/> before protocol II (TP3)	BM smears*		Heparin-BM	
<b>Control arm</b>				
<input type="checkbox"/> start Maintenance (TP MR contr. 1)	BM smears*		Heparin-BM	
<input type="checkbox"/> day 29 Maintenance (TP MR contr. 2)	BM smears*		Heparin-BM	
<b>Experimental arm</b>				
<input type="checkbox"/> start Blina Cycle (TP MR Blina d1)	BM smears*	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 29 Blina Cycle (TP MR Blina d29)	BM smears*	Heparin-BM	Heparin-BM	
<b>R-T (T-ALL)</b>				
<input type="checkbox"/> day 57 Protocol IB/2 (TP1b)	BM smears*			

\* Sample will not be analyzed routinely. Asservation only, if nothing else requested.

### Accompanying note IntReALL SR 2010

IntReALL SR 2010	Cyto-morphology	Immuno-phenotyping / FCM-MRD	Molecular-genetics / PCR-MRD	Cytogenomics
<input type="checkbox"/> relapse diagnosis	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> week 3 (Arm A/B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 5 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 6 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 9 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 10 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 13 (Arm A/B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 15 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 16 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> after HSCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

### Accompanying note IntReALL HR 2010

IntReALL HR 2010	Cyto-morphology	Immuno-phenotyping / FCM-MRD	Molecular-genetics / PCR-MRD	Cytogenomics
<input type="checkbox"/> relapse diagnosis	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> week 5 (before HC1)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 8 (before HC2)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 11 (before HC3)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> before HSCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

### Accompanying note EsPhALL2017/COGAALL1631

EsPhALL2017/COGAALL1631	Cyto-morphology	Immuno-phenotyping / FCM-MRD	Molecular-genetics / PCR-MRD	Cytogenomics
<input type="checkbox"/> Initial	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> after protocol IB	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> after Consolidation 3	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> before HSCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

## Accompanying note Mye Child 01

MyeChild 01	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
<input type="checkbox"/> initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM Heparin-PB	Heparin-BM
<b>Course 1</b>				
<input type="checkbox"/> post course 1	BM smears	Heparin-BM	Heparin-BM Heparin-PB	
<b>Course 2</b>				
<input type="checkbox"/> post course 2	BM smears	Heparin-BM	Heparin-BM Heparin-PB	
<b>Course 3</b>				
<input type="checkbox"/> post course 3	BM smears*	Heparin-BM	Heparin-BM Heparin-PB	
<input type="checkbox"/> before HSCT (if applicable)	BM smears*	Heparin-BM	Heparin-BM Heparin-PB	
<input type="checkbox"/> end of therapy	BM smears*	Heparin-BM	Heparin-BM Heparin-PB	
<b>HSCT (if applicable)</b>				
<input type="checkbox"/> 1 month after HSCT (if applicable)		Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 100 after HSCT (if applicable)		Heparin-BM	Heparin-BM	
<input type="checkbox"/> 6 months after HSCT (if applicable)		Heparin-BM	Heparin-BM	
<input type="checkbox"/> 9 months after HSCT (if applicable)		Heparin-BM	Heparin-BM	
<input type="checkbox"/> 12 months after HSCT (if applicable)		Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

\* Sample will not be analyzed routinely. Storage only, if nothing else requested.

## Accompanying note ML-DS 2018

ML-DS 2018	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
<input type="checkbox"/> initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> day 28 *	BM smears	Heparin-BM *	Heparin-BM *	
<input type="checkbox"/> day 56	BM smears		Heparin-BM	
<input type="checkbox"/> day 84	BM smears		Heparin-BM	
<input type="checkbox"/> day 112	BM smears		Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

\* **ML-DS study patients: additional shipment on day 28 by the local clinic to the ML-DS reference laboratory in Frankfurt (acc.to. CH-Appendix):**  
-1-5 ml bone marrow (Heparin or EDTA) for Immunphenotyping  
-4 ml bone marrow (EDTA) for Moleculargenetics

### Accompanying note Pediatric Relapsed AML 2010/01 (Protocol therapy)

Pediatric Relapsed AML 2010/01		Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
<input type="checkbox"/>	initial	BM smears PB smears CSF cytopins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/>	day 21	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/>	day 28	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/>	day 42-56	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/>	before HSCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/>	other timepoint:	*	*	*	*